E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
locally advanced or metastatic NRAS mutant melanoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In the phase Ib, the primary purpose is to establish the maximum tolerated dose (MTD (s)/recommended phase ll dose (RP2D) of the LEE011 and MEK162 orally administered combination. Once the MTD(s)/RP2D have been determined, the PhII part will begin in order to assess antitumor activity of LEE011and MEK162 orally administered combination. |
|
E.2.2 | Secondary objectives of the trial |
This study will also assess the safety, tolerability, PK and preliminary evidence of antitumor activity of the LEE011-MEK162 combination in NRAS mutated melanoma patients |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients must have an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 - 1
- Patients enrolled into phase Ib may be enrolled with evaluable disease
only. Patients enrolled into the phase II expansion must have at least
one measurable lesion as defined by RECIST 1.1 criteria.
- Patients must have adequate organ function, as defined by the
following parameters:
a. Bone marrow:
• Absolute Neutrophil Count (ANC) ≥ 1.5 x 10E9/L
• Hemoglobin (Hgb) ≥ 9 g/dL
• Platelets ≥ 75 x 10E9/L without transfusions within 21 days before 1st
treatment
• PT/INR and aPTT ≤ 1.5 ULN.
b. Serum creatinine ≤1.5 ULN
c. Hepatic function:
•Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
• Aspartate Aminotransferase (AST) (serum glutamic oxaloacetic
transaminase [SGOT]) and ALT (SGPT) ≤ 3 x ULN, except in patients
with tumor involvement of the liver who must have AST and ALT ≤ 5 x
ULN
|
|
E.4 | Principal exclusion criteria |
-Presence of any brain metastases detected by MRI or CT with i.v.
contrast of the brain at screening.
- Uncontrolled arterial hypertension despite medical treatment
- Impaired cardiac function or clinically significant cardiac diseases,
including any of the following:
a. Left ventricular ejection fraction (LVEF) < 50% as
determined by multiple gated acquisition scan (MUGA) or
echocardiogram (ECHO)
b. Congenital long QT syndrome or family history of unexpected sudden
cardiac death
c. QTc corrected with Frederica's or Bazett's formula (QTcF) >450 ms for
males and >470 ms for females on screening ECG
d. Angina pectoris ≤ 3 months prior to starting study drug, acute
myocardial infarction
≤ 3 months prior to starting study drug, clinically significant resting
bradycardia, history or presence of ventricular tachyarrhythmia,
unstable atrial fibrillation (ventricular response >100 bpm),
complete left bundle branch block, right bundle, branch block and left
anterior hemi block bifascicular block), obligate use of a cardiac
pacemaker or implantable cardioverter defibrillator and any other
clinically significant heart disease.
- Patients who are currently receiving treatment with agents that are
metabolized predominantly through CYP3A4 and that have a narrow
therapeutic window. Agents that are known strong inducers or inhibitors
CYP3A4 are
prohibited.
- Patients with concurrent severe and/or uncontrolled concurrent
medical conditions that could compromise participation in the study
(e.g.,
uncontrolled diabetes mellitus, clinically significant pulmonary disease,
clinically significant neurological disorder, active or uncontrolled
infection)
- History or current evidence of retinal vein occlusion RVO) or curent
risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension,
history of
hyperviscosity or hypercoagulability syndromes)
Other, protocol related exclusion criteria may apply. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. incident of dose limiting toxicities (Phase Ib)
2. objective response rate (Phase II) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. cycle 1 = 28 days (from the time of first dose)
2. baseline, every 2-4 months |
|
E.5.2 | Secondary end point(s) |
1. plasma concentration-time profiles of LEE011 and MEK162 (phase Ib)
2. Pharmacokinetics (PK) parameters including but not limited to AUCtau, Cmax, Tmax, CL/F, accumulation ration (Racc) and T1/2, acc2. incidence of adverse drug reactions
3. duration of response (phase II)
4. time to progression (phase II)
5. progression free survival (phase II)
6. overall survival (phase II)
7. best overall response (phase II) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-2. up to 24 weeks
3-7. approx. 12 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Germany |
Italy |
Netherlands |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Phase Ib and II of the study will end when the treatment period, safety
follow-up, disease follow-up and survival follow-up (only for phase II)
have ended for all patients as or when the study is terminated early. A
primary CSR will be written after all patients have completed at least
six cycles of treatment or discontinued treatment, and a final CSR will
be written at the end of the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |